In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pulmonary Artery Catheter Use Down Sharply, Research Shows

This article was originally published in The Gray Sheet

Executive Summary

Pulmonary artery catheterization in the United States - once common for critical care - has dropped so dramatically that it should either be discontinued entirely or performed only by physicians highly skilled in the procedure, according to articles in the July 25 Journal of the American Medical Association.

You may also be interested in...

Tufts Report Finds No Benefit From Routine Pulmonary Artery Catheterization

Pulmonary artery catheterization for monitoring cardiac function was once common in the intensive care units, but a new technology assessment requested by the government shows there is little evidence that the procedure is effective in critical care settings

German COVID-19 Testing Rate The Envy Of Others, With Demand Set To Climb

Germany has ramped up its COVID-19 testing capacity to 260,000 per week, and still has a relatively low death rate from the virus. The country's diagnostics industry says it is ready to play its part “24/7.”




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts